Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 4Gastrointestinal 2Breast 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Genitourinary 1Dermatologic 1Classical hematology 1

Conditions

Breast Neoplasms 117Triple Negative Breast Neoplasms 45Neoplasm Metastasis 11Pancreatic Neoplasms 8Inflammatory Breast Neoplasms 7Breast Neoplasms, Male 7Parkinson Disease 4, Autosomal Dominant Lewy Body 6Ovarian Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Stomach Neoplasms 4Neoplasms 4Lung Neoplasms 4Carcinoma, Ductal, Breast 4Sarcoma 3Prostatic Neoplasms 3Lymphoma, Non-Hodgkin 3Endometrial Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Hodgkin Disease 2Esophageal Neoplasms 2Carcinoma, Ovarian Epithelial 2Advanced Breast Cancer 2Thrombocytosis 1Stages II-III Breast Cancer 1Primary Myelofibrosis 1

Interventions

Therapeutics 6Cyclophosphamide 6Flow Cytometry 5Radiotherapy 4Peripheral Blood Stem Cell Transplantation 4Filgrastim 4pembrolizumab 3Psychiatric Rehabilitation 3Polymerase Chain Reaction 3Nivolumab 3Immunoenzyme Techniques 3Blood Specimen Collection 3sargramostim 2liposomal amphotericin B 2durvalumab 2copanlisib 2belinostat 2aldesleukin 2Vorinostat 2Surveys and Questionnaires 2Stem Cell Factor 2Rituximab 2Ondansetron 2Methylprednisolone 2Melphalan 2Itraconazole 2Ipilimumab 2Immunologic Techniques 2Gemcitabine 2Etoposide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hodgkin Disease × Albumin-Bound Paclitaxel × Breast × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT01929941 2018-01-17

An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies

Incyte Corporation

Phase 1 Terminated
5 enrolled
BreastGastrointestinalLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡